Article citationsMore>>
LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., Eskandar, E.N., Kostyk, S.K., Thomas, K., Sarkar, A., Siddiqui, M.S., Tatter, S.B., Schwalb, J.M., Poston, K.L., Henderson, J.M., Kurlan, R.M., Richard, I.H., Van Meter, L., Sapan, C.V, During, M.J. and Feigin, A. (2011) AAV2-GAD Gene Therapy for Advanced Parkinson’s Disease: A Double-Blind, Sham-Surgery Controlled, Randomized Trial. The Lancet Neurology, 10, 309-319.
https://doi.org/10.1016/S1474-4422(11)70039-4
has been cited by the following article:
-
TITLE:
Fractures in Parkinson’s Disease
AUTHORS:
Meghana Anagani, Terry Oroszi
KEYWORDS:
Parkinson’s Disease, Fractures, Antidepressants, Antipsychotics, Adverse Effects
JOURNAL NAME:
Health,
Vol.14 No.9,
September
20,
2022
ABSTRACT: Parkinson’s disease is a neurodegenerative disorder that is common in older people and is highly associated with depression, anxiety, apathy, psychosis, cognitive impairment, imbalance and sleep disturbances. These patients have an increased risk of fracture compared to the general population. Comprehensive searches of databases are performed to identify reviews about the risk of fractures in this disease. Parkinson’s patients are at increased risk for low bone mineral density due to the effect of drugs, Parkinson’s disease and age factor, leading to an increased risk of falling down and fractures, especially in the hip. So, improved and innovative treatments with the focus on minimizing inadvertent bone resorption with anti-Parkinson’s disease medication will be highly effective in reducing fear of the disease and providing the patient with a better quality of life.
Related Articles:
-
A. Natalia, H. Galadanci, S. A. Ibrahim, Z. Mohammad
-
Mark J.S. Miller, Ross Butler
-
Barbara Grube, Heike Stier, Linda Riede, Joerg Gruenwald
-
Johane Guay, Pierre Champagne, Pascal Guibord, Joerg Gruenwald
-
Manfred Schmolz, Reinhard W. März, Marco Schaudt, Cornelia Schaudt, Carola Lauster